Apotea (OM:APOTEA) has posted Q2 2026 revenue of SEK2.0b and basic EPS of SEK0.78, supported by net income of SEK81.4m, with the trailing twelve months showing revenue of SEK7.6b and EPS of SEK2.36. Over recent quarters the company has seen revenue move from SEK1.83b in Q2 2025 to SEK2.03b in Q2 2026, while quarterly EPS shifted from SEK0.69 to SEK0.78. This sets the backdrop for how investors assess the latest print. With trailing net profit margins slightly lower than a year ago and earnings forecasts pointing higher, the focus now is on how sustainably Apotea can defend and potentially rebuild its profitability profile.

See our full analysis for Apotea.

With the headline numbers on the table, the next step is to set these results against the most widely held narratives about Apotea to see which stories hold up and which ones start to look out of date.

See what the community is saying about Apotea

Apotea revenue keeps stepping up

• Quarterly revenue has moved from SEK1,753.5m in Q1 2025 to SEK2,029.5m in Q2 2026, while trailing twelve month revenue now stands at SEK7,595.7m, so Apotea is operating off a much larger top line than a year ago.
• Consensus narrative points to growing online prescription demand and warehouse capacity as key drivers, and the current numbers give some support to that view:
  • Trailing twelve month revenue of SEK7,595.7m sits well above the SEK6,772.9m reported a year earlier, which fits with the idea that the addressable online pharmacy market is expanding.
  • At the same time, net income on a trailing basis is SEK245.7m compared with SEK237.8m a year ago, which shows profits are tracking higher even as Apotea ramps infrastructure like the Varberg warehouse.

For investors who think this top line build out is the real story, it is worth seeing how that ties into the bullish community narrative for Apotea 🐂 Apotea Bull Case.

Margins softer at 3.2% despite higher EPS

• On a trailing twelve month view, Apotea has a net profit margin of 3.2% compared with 3.6% the prior year, even though quarterly net income has moved from SEK71.6m in Q1 2025 to SEK81.4m in Q2 2026.
• Bears focus on profitability pressure and cost intensity, and the reported figures give them material points to work with:
  • The margin slip from 3.6% to 3.2% aligns with concerns that higher Rx mix and warehouse depreciation can weigh on overall profitability even when revenue is higher.
  • With quarterly EPS fluctuating between SEK0.15 in Q4 2025 and SEK0.78 in Q2 2026, critics highlight that earnings can be sensitive to how efficiently Apotea utilises capacity in Morgongåva and Varberg and manages logistics and staffing costs.

If you are weighing these margin questions carefully, it can help to see how skeptics frame the more cautious case for Apotea 🐻 Apotea Bear Case.

Valuation tension at 33.7x P/E

• Apotea trades on a trailing P/E of 33.7x against an industry average of 18x and a peer average of 30.4x, while a DCF fair value of SEK115.38 and an analyst price target of SEK90.00 both sit above the current share price of SEK79.50.
• Supporters argue that growth forecasts justify this premium multiple, and the numbers show why this debate is so active:
  • Earnings are forecast to grow 22.3% per year and revenue 11.7% per year, which helps explain why the market is willing to pay more than the sector’s average multiple today.
  • At the same time, the stock is trading about 31.1% below the stated DCF fair value of SEK115.38, so investors are weighing that potential upside against the fact that margins most recently sat at 3.2% rather than the higher level seen the prior year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Apotea on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bullish and cautious Apotea narratives feels finely balanced, it may be worth taking prompt action to review the underlying data and stress test your own thesis. To see what investors find appealing right now, take a closer look at the 2 key rewards

See What Else Is Out There

Apotea is growing revenue, but softer 3.2% margins, cost intensity and a 33.7x P/E highlight that profitability and valuation risk remain front of mind.

If that mix of thinner margins and a premium multiple feels uncomfortable, it is worth urgently scanning the 290 resilient stocks with low risk scores to focus on stocks where earnings quality and balance sheet strength help limit downside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.